StreetAlpha.app
Home › Stocks › MANE

Veradermics, Inc (MANE)

Healthcare
$119.52
▼ −3.92%
LAST CLOSE · NOV 20

Veradermics develops VDPHL01, an oral, non-hormonal treatment for hair loss, from its base in New Haven, Connecticut. It last closed at $119.52 on Nov 20, down 3.92% on the day. The next earnings report for MANE is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, MANE reported EPS of -$0.50. Over its last 4 reports the stock moved an average of 4.0% the session after earnings. Over the last 12 months MANE insiders bought $54.1M of stock on the open market and sold $253.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is MANE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MANE.

Key Stats

Last 12 months
Results
Net income
−$93.6M
Free cash flow
−$82.6M
Valuation
Market cap
$5.0B
42.2M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$132.2M
At Sep 30
Shareholder equity
$796.5M
Shares outstanding
42.2M
At Nov 5
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2024: −$26.5M−$26.5MFY2024FY2025: −$70.0M−$70.0MFY2025

From MANE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$0.50
Quarter ended Sep 2026
Year ago EPS
-$30.15
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Mar 2025: -$19.79Mar '25Jun 2025: -$24.19Jun '25Sep 2025: -$30.15Sep '25Dec 2025: -$37.70Dec '25Mar 2026: -$1.32Mar '26Jun 2026: -$0.58Jun '26Sep 2026: -$0.50Sep '26Latest -$0.50
Revenue by quarter
Not enough quarters on file yet.
How MANE moved after its last 4 reports
Average move the session after a report ±4.0%
Nov 10, 2026Time not announced+3.1%
Aug 11, 2026Time not announced−1.6%
May 12, 2026Time not announced−3.9%
Mar 30, 2026Time not announced−7.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MANEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MANE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MANE

Technical Analysis

MANE · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 13% below its 20 day and 4% below its 50 day average. It is 19% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the Pivot S1 at $117.67, and the nearest resistance the Pivot at $120.84.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 7.2%/day
Key levels
$156.6352 week high+31.0%
$135.4420 day average+13.3%
$124.7050 day average+4.3%
$122.68Pivot R1+2.6%
$122.00Swing high (Sep 22)+2.1%
$120.84Pivot+1.1%
$119.52Last close
$117.67Pivot S1−1.5%
$116.48100 day average−2.5%
$108.77Swing low (Oct 6)−9.0%
$97.38200 day average−18.5%
$32.0052 week low−73.2%
Indicators
RSI (14)41.75Middle of its rangeNeutral
MACD-0.24Below its signal lineBearish
Stochastic5.1Near the bottom of its rangeOversold
ADX (14)20.1Weak trend
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-151.3Oversold below −100, overbought above 100Oversold
Rate of change−13.9%Change over 10 sessionsBearish
ATR (14)$8.61Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for MANE

What happened before

See how MANE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for MANEHow many large options trades hit MANE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

MANE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲136 buying vs 70 selling
  • ▲Held by funds +5.5 pts
  • ▲Funds holding +43
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding208165+26.1%
In funds' top 1068−25.0%
Held by funds86.3%80.8%+5.5 pts
New / increased60 / 7695 / 42−0.7%
Reduced / sold out53 / 1719 / 14+112.1%
Put/call ratio0.73––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MANE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MANE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$54.1M5 buys · 5 insiders
Sold$253.5M6 sales · 6 insiders
5% of the selling was under pre-arranged trading plans.
Cluster buy: 5 insiders bought $54.1M between Feb 4 and Feb 6.
2026-02 bought $54.1M2026-08 sold $103.1M2026-11 sold $150.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11Longitude Capital Partners V, LLC10% ownerSale500,000$150.38$75.2M
Nov 11Patrick G EnrightDirectorSale500,000$150.38$75.2M
Aug 19Montanova Capital, LLCDirectorSale750,000$107.25$80.4M
Aug 17Reid Alexander WaldmanCEOSale plan67,500$107.86$7.3M
Aug 17Timothy August DursoChief Technical OfficerSale plan43,500$107.82$4.7M
Aug 12John W ChildsDirectorSale100,000$107.12$10.7M
Every insider buy and sale for MANE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MANE insider trades →

From SEC Form 4 filings by MANE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MANE is in one of them and how their past MANE trades turned out.

MANE in the AI portfolios
Loading…

MANE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MANE in an article yet. Here's the latest on the wider market.

MANE in the news

About Veradermics

Veradermics is a biopharmaceutical company based in New Haven, Connecticut, that is developing treatments for hair loss. Its main product in development, VDPHL01, is an oral, extended-release form of minoxidil, a drug already used to grow hair, and it is designed to be non-hormonal. The company is running clinical trials in men and women with this condition and does not yet have an approved product. Its target customers are patients with hair loss and the dermatologists who treat them.

Headquarters
New Haven, CT